Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. 2006N-0425]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Fax written comments on the collection of information by March 30, 2007.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974.
 FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1472.


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance: Premarket Notification—21 CFR Part 807; Subpart E—(OMB Control Number 0910-0120)—Extension Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360(k)) and the implementing regulation under part 807 (21 CFR part 807, subpart E) require a person who intends to market a medical device to submit a premarket notification submission to FDA at least 90 days before proposing to begin the introduction, or delivery for introduction into interstate commerce, for commercial distribution of a device intended for human use. Based on the information provided in the notification, FDA must determine whether the new device is substantially equivalent to a legally marketed device, as defined in § 807.92(a)(3). If the device is determined to be not substantially equivalent to a legally marketed device, it must have an approved premarket approval application (PMA), Product Development Protocol or be reclassified into Class I or Class II before being marketed. The FDA makes the final decision of whether a device is equivalent or not equivalent. The Medical Device User Fee and Modernization Act of 2002 (MDUFMA) (Public Law 107-250) added section 510(o) to the act to establish new regulatory requirements for reprocessed single-use devices (SUDs). MDUFMA was signed into law on October 26, 2002. Section 510(o) of the act requires that FDA review the types of reprocessed SUDs subject to premarket notification requirements and identify which of these devices require the submission of validation data to ensure their substantial equivalence to predicate devices. Section 510(o) also requires that FDA review critical and semi-critical reprocessed SUDs that are currently exempt from premarket notification requirements and determine which of these devices require the submission of premarket notifications to ensure their substantial equivalence to predicate devices. FDA has identified the reprocessed SUDs that require the submission of validation data to date. The requirement to submit validation data for certain reprocessed single-use devices has been incorporated into the premarket notification program. As with all other devices, new premarket notifications for reprocessed SUDs will be required as new manufacturers enter the market or manufacturers with cleared premarket notifications make significant changes to their device. The burden estimates in this document include the burden for submitting premarket notifications for reprocessed SUDs with the burden for all other devices. FDA may amend the lists of reprocessed SUDs that require the submission of premarket notifications with validation data as necessary. Section 807.81 states when a premarket notification is required. A premarket notification is required to be submitted by a person who is: Introducing a device to the market for the first time;
                Introducing or reintroducing a device which is significantly changed or modified in design, components, method of manufacturer, or the intended use that could affect the safety and effectiveness of the device. Section 807.87 specifies information required in a premarket notification submission. Section 204 of the Food and Drug Administration Modernization Act 
                    ( print page 9006)
                    (FDAMA) amended section 514 of the act (21 U.S.C. 360d). Amended section 514 allows FDA to recognize consensus standards developed by international and national organizations for use in satisfying portions of device premarket review submissions including premarket notifications or other requirements. FDA has published and updated the list of recognized standards regularly since enactment of FDAMA and has allowed 510(k) submitters to certify conformance to recognized standards to meet the requirements of § 807.87. Certification of conformance to a recognized standard may allow a manufacturer to submit an abbreviated 510(k). FDA is now seeking approval of a form (Form FDA 3654) that will standardize certification of conformance to a recognized standard. FDA believes that use of this form will simplify the certification process for 510(k) submitters and the review process for FDA. Form FDA 3514, a summary cover sheet form, has been created to assist respondents in categorizing 510(k) information for submission to FDA. This form also assists respondents in categorizing information for other FDA medical device programs such as PMAs, investigational device exemptions, and humanitarian device exemptions The total burden (1,000 hours) for Form FDA 3514 has been included in this information collection. Form FDA 3654 is used in the following information collections: 0910-0078, 0910-0231, and 0910-0332, but the burden is approved under this information collection (0910-0120). Under § 807.87(h), each 510(k) submitter must include in the 510(k) either a summary of the information in the 510(k) (510(k) summary) or a statement certifying that the submitter will make available upon request the information in the 510(k) (510(k) statement). If the 510(k) submitter includes a 510(k) statement in the submission, § 807.93 requires that the official correspondent of the firm make available within 30 days of a request all information included in the submitted premarket notification on safety and effectiveness. This information will be provided to any person within 30 days of a request if the device described in the premarket notification submission is determined to be substantially equivalent. The information provided will be a duplicate of the premarket notification submission including any safety and effectiveness information, but excluding all patient identifiers and trade secret and confidential information. In the 
                    **Federal Register**
                     of November 3, 2006 (71 FR 64711), FDA published a 60-day notice requesting public comments on the proposed collection of information. In response to that notice, no comments were received. The most likely respondents to this information collection will primarily be medical device manufacturers including reprocessors of single-use devices, and initial importers of devices. FDA estimates the burden of this collection of information as follows: **Table 1.—Estimated Annual Reporting Burden**1
21 CFR Section
FDA Form
                             Number
Number of
                             Respondents
Annual Frequency
                             per Response
Total Annual
                             Responses
Hours per
                             Response
Total Hours807 Subpart E (807.81, 807.87, 807.92, & 807.93)

3,700
1
3,700
80
296,000807.87
3514
1,956
1
1,956
0.5
978807.90(a)(3)
3541
400
1
400
0.25
100807.87(d) and (f)
3654
150
1
150
1
150Totals





297,2281
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 **Table 2.—Estimated Annual Recordkeeping Burden**1
21 CFR Section
No. of
                             Recordkeepers
Annual Frequency per
                             Recordkeeping
Total Annual
                             Records
Hours per
                             Recordkeeper
Total Hours807.93
2,000
10
20,000
0.5
10,0001
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 
 
 FDA has based these estimates on conversations with industry and trade association representatives, and from internal review of the documents listed in tables 1 and 2 of this document. Dated: February 22, 2007. Jeffrey Shuren, Assistant Commissioner for Policy.


[FR Doc. E7-3444 Filed 2-27-07; 8:45 am] BILLING CODE 4160-01-S